Outlook Therapeutics, Inc. (OTLK)
| Market Cap | 25.37M -49.2% |
| Revenue (ttm) | 205,702 |
| Net Income | -102.86M |
| EPS | -2.35 |
| Shares Out | 104.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,209,520 |
| Open | 0.2435 |
| Previous Close | 0.2477 |
| Day's Range | 0.2265 - 0.2440 |
| 52-Week Range | 0.1611 - 3.3900 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 2.50 (+930.93%) |
| Earnings Date | May 14, 2026 |
About OTLK
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for OTLK stock is "Buy." The 12-month stock price target is $2.5, which is an increase of 930.93% from the latest price.
News
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
ISELIN, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of c...
Outlook Therapeutics to sell 16.129M shares at 31c in registered direct offering
Outlook Therapeutics (OTLK) announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 16.129M shares of its common stock at an offering…
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
ISELIN, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics” or the “Company”), a biopharmaceutical company focused on enhancing the standard of c...
Outlook Therapeutics completes Federal Dispute Resolution meeting with FDA
Outlook Therapeutics (OTLK) announced that it has completed its Federal Dispute Resolution meeting with the Office of New Drugs at the U.S. Food and Drug Administration. The meeting was conducted…
Outlook Therapeutics Completes Federal Dispute Resolution (FDR) Meeting with FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
ISELIN, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r...
Outlook Therapeutics submits formal dispute resolution request to FDA
Outlook Therapeutics (OTLK) announced that it submitted a formal dispute resolution request to the FDA as a follow-up to its recent Type A meeting regarding the December 30, 2025 Complete…
Outlook Therapeutics Announces Formal Dispute Resolution Request for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Accepted by FDA
ISELIN, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r...
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering
ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r...
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
ISELIN, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r...
Outlook Therapeutics announces common stock, warrant offering, no amount given
Outlook Therapeutics (OTLK) announced that it has commenced a best-efforts public offering of its common stock and accompanying warrants exercisable for shares of its common stock. H.C. Wainwright & C...
Outlook Therapeutics Announces Proposed Public Offering
ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r...
Outlook Therapeutics announces $18.4M non-convertible note financing
Outlook Therapeutics (OTLK) announced an amendment to its existing convertible note with Avondale Capital and the issuance of a new non-convertible, unsecured note with Atlas Sciences,. Under the amen...
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note
ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r...
Outlook Therapeutics price target lowered to $6 from $10 at Ascendiant
Ascendiant lowered the firm’s price target on Outlook Therapeutics (OTLK) to $6 from $10 and keeps a Buy rating on the shares following the Q1 report.
Outlook Therapeutics provides update following FDA meeting on ONS-5010
Outlook Therapeutics (OTLK) provided an update following its recent Type A meeting with the FDA to discuss the December 30, 2025 complete response letter for the biologics license application, or…
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)
ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of r...
Outlook enters distribution agreement for sale of Lytenava in Switzerland
Outlook Therapeutics (OTLK) announced they have entered into an exclusive commercial distribution agreement for the sale and distribution of Lytenava in the Switzerland market. Under the terms of the ...
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partner Mediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA...
Outlook Therapeutics reports adjusted Q1 EPS (22c), consensus (17c)
“Lytenava is demonstrating increasing adoption in Europe following our initial launches, with growing demand and quarter-over-quarter unit sales growth,” said Bob Jahr, Chief Executive Officer of Outl...
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
ISELIN, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re...
Outlook Therapeutics sumbits Type A meeting request to FDA
Outlook Therapeutics (OTLK) submitted a Type A meeting request to the U.S. Food and Drug Administration following receipt of a Complete Response Letter dated December 30, regarding the Company’s Biolo...
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re...
Outlook Therapeutics appoints Laura Cantrell as VP, corporate strategy
Outlook Therapeutics (OTLK) has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. In her role as Vice President of Corporate Strategy and Business Development,...
Largest borrow rate increases among liquid names
Latest data shows the largest indicative borrow rate increases among liquid option names include: Outlook Therapeutics Inc (OTLK) 81.97% +33.92, T-REX 2X LONG MSTR DAILY TARGET (MSTU) 55.54% +10.13, V...
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re...